Market: NYSE |
Currency: USD
Address: 101 Lindenwood Drive
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
Show more
📈 Annovis Bio, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$12.33
-
Upside/Downside from Analyst Target:
433.91%
-
Broker Call:
6
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Annovis Bio, Inc.
| Date | Reported EPS |
|---|
| 2025-08-12 | -0.32 |
| 2025-05-13 | -0.32 |
| 2025-03-21 | -0.43 |
| 2024-11-08 | -0.97 |
| 2024-08-14 | -0.44 |
| 2024-05-10 | -0.1 |
| 2024-03-29 | -2.33 |
| 2023-11-08 | -1.63 |
| 2023-08-14 | -1.07 |
| 2023-05-10 | -1.19 |
| 2023-03-31 | -0.38 |
| 2022-11-08 | -0.93 |
| 2022-08-08 | -1.07 |
| 2022-05-04 | -0.72 |
| 2022-03-02 | -0.75 |
| 2021-11-03 | -0.35 |
| 2021-07-28 | -0.34 |
| 2020-11-04 | -0.15 |
| 2020-07-29 | -0.34 |
📰 Related News & Research
No related articles found for "annovis bio".
